How to efficiently move towards primary prevention in sporadic AD
Optimizing clinical trial design is essential for advancing Alzheimer's prevention on a global scale. Building large international cohorts with "run-in" plasma biomarker data with global collaborations will serve to accelerate the development and accessibility of Alzheimer's prevention solutions.
Authors
- REMA RAMAN (ORCID: https://orcid.org/0000-0002-4096-6390)
- Reisa A. Sperling
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105951
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00